Beijing University of Chinese Medicine

Chaoyang, China

Beijing University of Chinese Medicine (BUCM), established in 1956, is one of China's earliest institutions dedicated to traditional Chinese medicine (TCM) education and research
Add to compare
4.5k
4k
250
500
160
54
33:3
0
60 %
1201-1400

Tuition Fees, Cost of Living & Accommodation at Beijing University of Chinese Medicine

Cost Of Living

¥ 33600

Undergraduate Fees International Students

¥ 35000

Post Graduate Fees International Students

¥ 37500

Beijing University of Chinese Medicine Departments

  • School of Traditional Chinese Medicine
  • School of Integrated Traditional Chinese and Western Medicine
  • School of Acupuncture, Moxibustion, and Tuina
  • School of Clinical Medicine
  • School of Nursing
  • School of Pharmaceutical Sciences
  • School of Management
  • School of Humanities
  • International College
  • Chinese Language and Culture School

Distinguished Alumni of Beijing University of Chinese Medicine

Step-by-Step Guide to Admission Requirements at Beijing University of Chinese Medicine

admission requirements for international undergraduate applicants to Beijing University of Chinese Medicine (BUCM):

Valid Foreign Passport
Applicants must hold a valid foreign passport. For those who were previously Chinese citizens, the passport must have been obtained before April 30, 2017, and they must have proof of renunciation of Chinese nationality before this date. Additionally, applicants should have a record of actual residence abroad for more than two years between April 30, 2017, and April 30, 2021 .

Age Requirement
Applicants should be 18 years old or above as of December 31, 2021. Those under 18 are required to submit a guardian guarantee letter .

Educational Background
Applicants must have completed high school or possess an equivalent qualification. Graduates should provide their graduation certificate and academic transcript, either in Chinese or English .

Language Proficiency

Chinese Program: Applicants whose native language is not Chinese need to provide an HSK level 4 (inclusive) or above certificate.

Bilingual Program (Chinese and English): Applicants whose native language is not English need to provide score reports of TOEFL/IELTS or relevant English proficiency tests .

Application Form
Completion of the BUCM Application Form for Undergraduate Admission for International Students, available on the official website of the International School .

Passport-sized Photos
Submission of two recent passport-sized photos.

Self-introduction Video
A video of approximately five minutes introducing oneself. Some applicants may also be required to attend an online interview .

Application Fee
Payment of a non-refundable application fee of 800 RMB. Once paid, the fee will not be refunded if the applicant is not admitted or if the application is ineligible .

Additional Documents
Optional submission of a personal statement, reference letters, and relevant certificates for talents and skills (e.g., award certificates or proficiency certificates) .

Health and Character Requirements
Applicants must possess good moral character and be in good physical and mental health, meeting the medical examination standards required for obtaining a study visa or residence permit for studying in China .

 

Know more

Beijing University of Chinese Medicine Corporate Partnership

  • China National Pharmaceutical Group (Sinopharm) : Beijing University of Chinese Medicine has partnered with China National Pharmaceutical Group (Sinopharm) to advance research in the field of traditional Chinese medicine (TCM). This collaboration focuses on the development of TCM-based pharmaceuticals, with a particular emphasis on integrating modern biomedical research with ancient healing practices. Through this partnership, BUCM and Sinopharm have worked together to develop herbal treatments and natural remedies that address a variety of health issues. The partnership has helped BUCM enhance its research capabilities and bring TCM-based solutions to the global market.
  • Bayer Pharmaceuticals : In collaboration with Bayer Pharmaceuticals, BUCM has engaged in joint research initiatives aimed at bridging the gap between modern medicine and TCM. This partnership focuses on exploring how traditional herbal formulas can complement contemporary pharmaceuticals, especially in the treatment of chronic diseases such as diabetes and cardiovascular conditions. BUCM's research efforts, combined with Bayer’s advanced pharmaceutical expertise, have resulted in new insights and innovative treatments, benefiting patients worldwide. This collaboration highlights the growing recognition of TCM’s potential in the international healthcare market.
  • China National Traditional Chinese Medicine Group : BUCM has established a strategic partnership with the China National Traditional Chinese Medicine Group, one of China’s largest TCM-based pharmaceutical companies. This collaboration primarily focuses on the research and development of TCM drugs and therapies. BUCM’s academic expertise and research capabilities complement the corporate entity’s focus on the commercialization of TCM products. The partnership has resulted in the successful development of several products that integrate TCM with modern healthcare solutions. This collaboration contributes to the growing acceptance and popularity of Chinese medicine on a global scale.
  • Tongrentang : Tongrentang, a leading Chinese medicine company, has formed a key partnership with BUCM to promote the research and commercialization of traditional Chinese medicine products. The collaboration involves joint research initiatives focused on developing new herbal medicines and improving existing formulations. Tongrentang’s expertise in manufacturing and distribution complements BUCM’s strong research foundation, helping to bring traditional remedies to modern healthcare markets. This collaboration has led to the development of innovative products that address a range of medical conditions, supporting the global recognition of TCM as a viable healthcare option.
  • Zhongtai International Holdings Ltd. : Zhongtai International Holdings Ltd., a multinational investment and financial services group, has partnered with BUCM to explore opportunities in the development of TCM-based health products. The collaboration focuses on the commercial aspects of TCM, including product manufacturing, distribution, and market expansion. By leveraging Zhongtai’s business acumen and BUCM’s research capabilities, the partnership aims to bring TCM products to new markets, particularly in Europe and North America. This partnership plays a significant role in driving the global recognition and acceptance of TCM as a viable healthcare alternative.
  • Lilly China : The collaboration between BUCM and Lilly China, a subsidiary of the global pharmaceutical company Eli Lilly, focuses on exploring the intersection between Western medicine and TCM in the treatment of metabolic disorders, such as diabetes. Through joint research, the partnership has worked on identifying potential synergies between Lilly’s pharmaceutical products and BUCM’s traditional Chinese therapies. This partnership underscores BUCM’s commitment to expanding the evidence base for TCM and validating its efficacy in treating modern health challenges. By blending TCM with advanced pharmacological approaches, the collaboration aims to provide more comprehensive treatment options.
  • Beijing Tongrentang Co., Ltd. : BUCM has also forged an important partnership with Beijing Tongrentang Co., Ltd., a well-established name in TCM medicine manufacturing. This partnership focuses on combining BUCM’s research capabilities with Tongrentang’s extensive experience in product development and marketing. Together, they work on formulating and commercializing new TCM-based health products, ensuring that they meet both traditional standards and modern scientific criteria. Through this collaboration, BUCM continues to play a key role in preserving and promoting TCM while integrating modern scientific practices to improve patient care.
View More

Notable Achievements of Beijing University of Chinese Medicine

Achievements

01.
Awarded National Excellence in Teaching

In 2021, BUCM received the prestigious National Excellence in Teaching award from the Ministry of Education of the People’s Republic of China. This award recognized the university’s outstanding contributions to the development of high-quality education in TCM and its commitment to producing skilled and knowledgeable practitioners. BUCM’s innovative teaching methods, combined with its strong emphasis on research and practical application, have positioned it as a leading institution in the field. The award reflects BUCM’s ongoing efforts to elevate the standard of TCM education in China and internationally.

Year
2021
02.
Development of a Traditional Chinese Medicine Online Platform

In 2020, BUCM launched an online platform dedicated to the dissemination of TCM knowledge and education. The platform offers courses, webinars, and resources on Chinese medicine, acupuncture, and herbal therapies, reaching a global audience. The initiative was particularly timely, as it provided an accessible way for students and practitioners around the world to learn about TCM during the COVID-19 pandemic. BUCM’s online platform has expanded its educational outreach, allowing people from diverse backgrounds and locations to explore the benefits of Chinese medicine, while promoting international collaboration and exchange in the field.

Year
2020
03.
Ranking in the Top 400 Asian Universities

In 2019, BUCM achieved a major milestone by being ranked among the top 400 universities in Asia according to the QS Asia University Rankings. This recognition highlighted BUCM’s global influence in the fields of Chinese medicine, research, and academic excellence. The university’s strengths in faculty quality, international student numbers, and low student-to-faculty ratio contributed to its top ranking. The achievement marked BUCM as a leading institution not just in China, but also in Asia, solidifying its status as a center of excellence for TCM education and research on a global scale.

Year
2019

Notable Innovation, Research & Development Beijing University of Chinese Medicine

Notable Innovation

01.
Traditional Chinese Medicine for Mental Health

In 2022, BUCM developed a unique treatment combining traditional Chinese medicine and modern therapeutic practices to address mental health issues, particularly anxiety and depression. The treatment includes a combination of acupuncture, herbal remedies, and mindfulness techniques derived from TCM. Research demonstrated that this integrated approach could significantly reduce symptoms of anxiety and depression, offering a holistic alternative to pharmaceutical treatments. This innovation has gained recognition in the mental health field for its ability to treat the root causes of mental health issues, rather than just alleviating symptoms.

Year
2022
02.
Innovative TCM-based Weight Loss Formula

In 2021, BUCM researchers introduced an innovative weight loss formula based on traditional Chinese herbs. The formula combines herbs known for their metabolism-boosting and appetite-suppressing properties, offering a natural alternative to weight loss supplements. Extensive research on the pharmacological effects of these herbs showed significant weight reduction and improvement in fat metabolism among trial participants. The formula has been incorporated into several weight loss programs in China, with plans for international distribution due to its positive impact on weight management and overall health.

Year
2021
03.
Herbal-based Anti-inflammatory Formula

In 2020, BUCM researchers developed an herbal-based anti-inflammatory formula that combines traditional Chinese herbs with modern pharmacological agents to treat chronic inflammation. The formula was specifically designed to address autoimmune conditions, such as rheumatoid arthritis and inflammatory bowel disease, using the natural properties of herbs to modulate immune system activity. Extensive clinical trials showed that the formula significantly reduced inflammation and alleviated pain, offering a natural alternative to synthetic drugs. The success of this formula has led to its commercialization and use in both domestic and international healthcare markets.

Year
2020

University Ranking of Beijing University of Chinese Medicine

1201-1400
1501

Region: BRICS

499
401-450
201-210
Life Sciences
501-520
-
-
-
Medicine
-
635
-
-
Pharmaceutical Toxicology
-
246
-
-

Connect With Beijing University of Chinese Medicine

  • 11 N 3rd Ring Rd E, Chaoyang Qu

Book Free Session with Our Admission Experts

Admission Experts